ARTEMIDE-Biliary01_D7025C00001 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)https://www.nct-dresden.de/en/trials/900-000002444https://www.nct-dresden.de/@@site-logo/logo-nct.svg
ARTEMIDE-Biliary01_D7025C00001 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Gastrointestinal tumors
Hepatobiliary tumors
Adjuvant Therapy
A global study to assess the efficacy and tolerability of rilvegostomig compared toplacebo in combination with investigator's choice of chemotherapy in participants withBTC after surgical resection with curative intent.
A Phase III, Randomized, Double-Blind, Placebo-Controlled,
Multicenter, Global Study of Rilvegostomig in Combination With
Chemotherapy as Adjuvant Treatment After Resection of Biliary
Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
